600789 鲁抗医药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入4,666,959-1.37%6,146,7215,621,4424,923,7844,205,109
减:营业总成本4,545,911-0.57%5,907,6645,455,3694,793,3894,142,309
    其中:营业成本3,648,5870.39%4,631,2684,373,9623,746,1053,224,977
               财务费用45,2391.92%66,63978,20168,15967,741
               资产减值损失3,518-129.29%(54,682)(41,938)(30,942)(22,030)
公允价值变动收益47216.67%(69)52113(57)
投资收益(5,913)55.86%(7,134)(6,582)(3,296)2,598
    其中:对联营企业和合营企业的投资收益(5,913)55.86%(7,169)(6,611)(3,295)2,481
营业利润372,54068.43%272,133148,774116,019264,885
利润总额372,32867.84%272,975150,095113,579262,161
减:所得税费用15,409-29.61%16,1886,98023,68728,676
净利润356,91978.51%256,787143,11589,891233,485
减:非控股权益9,86133.35%10,6155,1027935,608
股东净利润347,05880.24%246,172138,01389,099227,877

市场价值指针
每股收益 (元) *0.39077.27%0.2800.1600.1000.260
每股派息 (元) *0.020--0.0900.0550.0500.055
每股净资产 (元) *4.3329.44%4.0313.7853.6953.651
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容